Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Pfizer rose $0.65 (2.3%) to $29.37 on average volume. Throughout the day, 33,309,364 shares of Pfizer exchanged hands as compared to its average daily volume of 31,618,400 shares. The stock ranged in a price between $28.67-$29.37 after having opened the day at $28.75 as compared to the previous trading day's close of $28.72. Other companies within the Drugs industry that increased today were: Alimera ( ALIM), up 27.3%, Opexa Therapeutics ( OPXA), up 26.0%, Theravance ( THRX), up 17.9% and MediciNova ( MNOV), up 16.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $205.5 billion and is part of the health care sector. The company has a P/E ratio of 23.3, above the S&P 500 P/E ratio of 17.7. Shares are up 14.5% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Genvec ( GNVC), down 33.6%, Redhill Biopharma ( RDHL), down 7.9%, Savient Pharmaceuticals ( SVNT), down 5.0% and Cleveland BioLabs ( CBLI), down 4.9% , were all laggards within the drugs industry with Illumina ( ILMN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.